Is SAP Business One relevant for chemical production businesses?

| January 21, 2020

article image
Chemical production is essential to the creation of many commercial products like medicines, food additives, pesticides, cosmetics, paints, and plastics—items people rely on every day.  It’s an industry where safety and quality are paramount concerns, meaning the regulatory landscape for process manufacturers that produce chemicals is complex. But maintaining compliance, quality control, and traceability is the bare minimum. Manufacturers of chemicals must also consider both new products and new business models to remain competitive in a more commoditised and regulated marketplace.

Spotlight

Dicerna Pharmaceuticals, Inc.

Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, known as RNA interference or RNAi, uses the body’s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. Dicerna is advancing a growing pipeline of product candidates, with our DCR-PHXC lead program in preclinical development for the treatment of a progressive and debilitating rare disease called primary hyperoxaluria, or PH.We expect to launch additional GalXC™ programs in HBV, cardiovascular disease targeting PCSK9, and another in an undisclosed genetic ra

OTHER ARTICLES
CHEMICAL MANAGEMENT

Southeast polyolefins demand growth could be negative again in 2021

Article | July 13, 2021

BEFORE the pandemic, GDP growth rates in the developing world were always higher than in developed economies.And because developing economies had much lower levels of petrochemicals consumption than their rich counterparts, it meant that the multiples over GDP were higher than in the rich word, where consumption was pretty much saturated. For instance, polyethylene (PE) demand in a developed country such as Germany might have grown at 0.3% times GDP whereas in Indonesia the growth could have been one or more times higher than the rate of growth in GDP.But as The Economist wrote in this 11 July article: “In 2021 the poorest countries, which are desperately short of vaccines, are forecast to grow more slowly than rich countries for only the third time in 25 years.” Might the multiples over GDP growth also be adversely affected in the developing world, trending lower than the historic norms? They will almost certainly remain higher than the rich countries. But here is the thing: as millions more people are pushed back into extreme poverty by the pandemic or are denied the opportunity to achieve middle-income status, I believe that developing-world multiples may well decline.Escaping extreme poverty means being able to, say, afford a whole bottle of shampoo for the first time rather than a single-serve sachet, thereby raising per capita polymers consumption.

Read More
CHEMICAL MANAGEMENT

Pandemic’s third wave seems unlikely to damage global petrochemicals demand

Article | July 22, 2021

Petrochemical stocks plunged worldwide on 19 July ahead of the Q2 earnings season. The declines were consistent with those in economically sensitive sectors such as steel, copper, automotive and housing,” wrote my ICIS colleague, Joseph Chang, in this Insight article.

Read More
CHEMICAL TECHNOLOGY

Reimagining the Workforce with Anglo American

Article | June 21, 2021

“At Anglo-American, we’re really focused on finding the best ways to attract the most talented people in the industry and effectively equipping our existing workforce based on what they need today and what the future will mean for their careers. We’re also committed to providing learning opportunities that lead to growth and development in the communities in which we operate. Our people are a strategic advantage. We want to ensure that continues to be the case as the mining industry evolves and faces more disruption.

Read More
CHEMICAL MANAGEMENT

Energy portfolio restructuring: Charting the future

Article | June 17, 2021

Consumer needs and preferences in the energy industry are evolving. Environmental, social and governance (ESG) concerns are becoming more acute—inspiring action and shifting value towards low-carbon solutions. These trends accelerated in 2020 and for the first time, market capitalization of leading low-carbon solutions companies began to overtake those of oil and gas (O&G) majors. This is despite the majors laying out energy transition strategies, setting low carbon energy targets and generating higher revenues by an order of magnitude.1 In response to this radically changing landscape, energy companies are charting divergent courses for their futures. Some continue to bet on their ability to generate returns from the O&G value chain. They are focusing on growing margins and lowering carbon intensity. Others are supplementing their capabilities with low-carbon energy solutions or exiting hydrocarbons altogether. This blog focuses on the path forward for the energy majors in Europe who are betting big on diversification.

Read More

Spotlight

Dicerna Pharmaceuticals, Inc.

Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, known as RNA interference or RNAi, uses the body’s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. Dicerna is advancing a growing pipeline of product candidates, with our DCR-PHXC lead program in preclinical development for the treatment of a progressive and debilitating rare disease called primary hyperoxaluria, or PH.We expect to launch additional GalXC™ programs in HBV, cardiovascular disease targeting PCSK9, and another in an undisclosed genetic ra

Events